明發集團(00846.HK)估計6間中國附屬公司董事會建議重組事宜3月底前完成
格隆匯2月28日丨明發集團(00846.HK)公吿,於公吿日期:2間中國附屬公司已向地方負責監管機構提呈其董事變更申請並正在等待反饋及批准;及6間中國附屬公司("餘下中國附屬公司")正在準備申請變更董事的文件。
董事會持續監察上述事宜進展。鑑於爆發COVID-19新型變種病毒,以及嚴謹檢疫政策持續,公司估計餘下中國附屬公司董事會建議重組事宜將於2022年3月底前完成。董事會將繼續監察有關進展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.